Workflow
Royalties
icon
Search documents
Ligand Pharmaceuticals (LGND) 2024 Earnings Call Presentation
2025-07-02 15:33
Financial Performance and Guidance - Ligand's total revenue guidance for 2024 is $160-$165 million[21], with royalty revenue expected to be $105-108 million[22], representing a 27% increase from 2023[30] - The company anticipates adjusted EPS of $550-$570 in 2024[22], a 38% growth[30] - For 2025, Ligand forecasts total revenue of $180-$200 million[34], with royalty revenue growing by 30% over 2024[35] - Ligand projects royalty receipts to grow at a CAGR of 22% from 2024 to 2029[24, 40] Investment and Portfolio Activity - Ligand deployed $192 million across 8 different investments in 2024[21] - The company's Q4 pipeline includes over 30 actionable opportunities, representing over $1 billion of potential investments[61] - Ligand acquired Apeiron Biologics in July 2024 for approximately $100 million, gaining rights to Qarziba royalties[70] Key Products and Platforms - Ligand's Captisol platform is used in 16 approved products[99, 104] - Verona's Ohtuvayre, in which Ligand has royalty rights, achieved over $11 million in sales in the first 4 months following approval[75] - Travere's Filspari generated $356 million in Q3 2024, with 31% growth from Q2 2024[80] - Merck's Capvaxive, another royalty asset for Ligand, protects against strains that cause 84% of invasive pneumococcal disease[88]
CVW CleanTech Announces Results of Key AGM Voting Items
Newsfile· 2025-07-02 12:18
Core Points - CVW CleanTech Inc. announced that shareholders approved key resolutions at the annual general and special meeting, including an Industry Classification Change, Name Change, and an Equity Incentive Plan [1][2][4] Industry Classification Change - The Company received shareholder approval to change its listing status from a "technology issuer" to an "investment issuer," which has been finalized by the TSX Venture Exchange [2][3] - This change will provide the Company with greater flexibility in structuring investments and streamline regulatory approvals for future transactions, supporting its royalty diversification strategy [3] Name Change - Shareholders approved a resolution to change the Company's legal name to "CVW Sustainable Royalties Inc." The change is expected to take effect shortly, with the ticker symbol remaining unchanged [4][6] Equity Incentive Plan - The Company adopted a 10% rolling equity incentive plan, which was approved by shareholders. Details of the plan can be found in the Management Information Circular [5]
又一位歌手“下海”OnlyFans,真穷还是哭穷?
Hu Xiu· 2025-06-06 00:34
最近,纽约市议会通过了第368号决议,呼吁为艺术家提供公平的报酬,议会还支持通过2024年美国国会提出的《音乐家生计工资法案》。 那么,在流媒体时代,即便是有作品、稳定有听众的艺术家,也可能陷入债务泥潭吗?这究竟是个别艺术家的落魄趣闻,还是整个音乐产业系统性失衡的 缩影? 知名音乐人,为什么屡屡喊穷? 去年秋天,Kate Nash在结束北美和欧洲巡演后整理账目时,才意识到自己基本上要负债了,尤其是在她正为推广最新专辑《9 Sad Symphonies》而努力的 情况下。 对于一位从事音乐创作近二十年,并且能够售罄演唱会的资深音乐人来说,毫无疑问是令人担忧的。 回顾Kate Nash的职业生涯,2007年,她凭借其独立流行专辑《Made of Bricks》一举成名,获得了业界的广泛认可。这张专辑不仅让她赢得了商业上的成 功,也收获了批评界的高度赞誉。 之后,她陆续发行了几张专辑,并在演艺领域不断拓展自己的边界,甚至在Netflix剧集《GLOW》中出演角色,展现了多才多艺的形象。 直到去年11月,当她发现一堆未付款的账单时,才意识到,她或许需要另寻生路。在这种困境下,她做出了一个令人没那么意外的决定:加入 O ...
Sitio Royalties (STR) - 2025 Q1 - Earnings Call Transcript
2025-05-08 13:30
Sitio Royalties (STR) Q1 2025 Earnings Call May 08, 2025 08:30 AM ET Speaker0 Ladies and gentlemen, thank you for attending today's CTO Royalties First Quarter twenty twenty five Earnings Call. My name is Ada, and I will be your operator today. All lines will be muted during the presentation of the call. There's an opportunity for questions and answers at the end. I would now like to pass the conference over to our host, Alisa Stevens, Vice President of Investor Relations. Please go ahead. Speaker1 Thanks, ...
XOMA Royalty Corporation's Preferreds Still Offer Attractive Yields With A Biotech Twist
Seeking Alpha· 2025-04-08 04:24
Group 1 - XOMA Royalty Corporation focuses on acquiring royalties and milestone rights from biotech assets in early to mid-development stages [1] - The company offers a preferred stock, XOMAO, which yields a dividend of 8.375% and is cumulative [1]
OmniAb(OABI) - 2024 Q4 - Earnings Call Transcript
2025-03-18 21:32
OmniAb (OABI) Q4 2024 Earnings Call March 18, 2025 04:30 PM ET Company Participants Kurt Gustafson - CFOMatt Foehr - President & CEOPuneet Souda - Senior MD Conference Call Participants Joseph Pantginis - MD & Senior Healthcare AnalystMatt Hewitt - Senior Research AnalystSrikripa Devarakonda - AnalystNone - Analyst Operator Good afternoon and welcome to OmniAb Inc. Fourth Quarter and Full Year twenty twenty four Financial Results and Business Update Conference Call. At this time, all participants are in a l ...